What does MDSteps cost?

MDSteps lets new visitors start with a free-trial bridge page first. Full access is $27/month, with lifetime access available for $299. Monthly access can be canceled anytime.

How close are the practice questions to the real USMLE?

MDSteps uses NBME-style clinical vignettes with detailed rationales, signal-first explanations, differentiators, and stem-decoding review.

Can I target weak systems or disciplines?

Yes. Students can create focused blocks by Step, system, discipline, and weak areas, then use analytics and flashcards to review missed patterns.

Vasopressors & Shock: Norepi vs Epi vs Vasopressin vs Dobutamine (When and Why)

Build the mental model first: SVR vs CO vs “mixed” shock

USMLE shock questions reward a simple habit: before you name a drug, name the dominant physiologic failure. On exam day, you rarely get invasive hemodynamics—but you do get clues that map to either low systemic vascular resistance (SVR), low cardiac output (CO), or both. Your pressor/inotrope choice is just receptor pharmacology applied to that bucket.

Board-style hemodynamic translation

Warm extremities + bounding pulses + wide pulse pressure → think low SVR (often distributive).
Cool clammy skin + narrow pulse pressure → think low CO (often cardiogenic/obstructive).
High lactate / oliguria / altered mental status → poor perfusion regardless of BP.
Sepsis + new cardiomyopathy → mixed shock (low SVR and low CO).

Receptor “cheat map” (why each drug behaves the way it does)

Agent	Primary effect	Exam shorthand
Norepinephrine	α1 >> β1	“Raise SVR without crazy tachy”
Epinephrine	β1/β2 → α1 (dose dependent)	“More inotropy; more lactate/tachy”
Vasopressin	V1 vasoconstriction (non-catecholamine)	“Add-on to spare norepi”
Dobutamine	β1 > β2 (inotrope; can drop SVR)	“Fix low CO when BP can tolerate it”

USMLE tip: if the stem screams “vasodilated,” start with α support; if it screams “pump failure,” add β1 support.

One-pass shock sorting algorithm (exam-friendly)

Stabilize: airway/oxygenation; IV access; monitor; treat immediate arrhythmia.
Identify bucket: warm vs cold, pulse pressure, JVP/lung findings, infection clues.
Choose the first vasoactive: raise SVR first if vasodilated; support CO if failing.
Reassess perfusion: mental status, urine output, lactate trend, cap refill, skin temp.

NBME trap: “normal-ish” MAP does not equal adequate perfusion. Shock is a perfusion problem first.

Septic shock: why norepinephrine is first-line

Septic shock is the classic distributive picture: vasodilation (low SVR) plus capillary leak, often with a high-output phase early and a “septic cardiomyopathy” phase later. Your initial pressor choice should restore vascular tone while minimizing arrhythmias and excessive tachycardia—because tachycardia increases myocardial oxygen demand and can worsen perfusion in patients already vasoplegic.

Mechanism-to-stem matching for norepinephrine

α1 predominance → increases SVR and MAP, improving coronary/cerebral/renal perfusion pressure.
Some β1 → modest support of contractility (useful in mixed sepsis + myocardial depression).
Less β2 than epi → less reflex tachy and fewer arrhythmias compared with dopamine-like options.

Dosing anchors you can recognize on questions

Target MAP ≥ 65 mmHg (unless special context like chronic hypertension, per clinician judgment).
Start vasopressors promptly after adequate fluids; don’t wait forever for a central line on exam stems.
Reassess after each change: skin, mentation, urine output, lactate trend.

Why “not dopamine” is still high-yield

The USMLE point isn’t that dopamine never works; it’s that dopamine increases arrhythmias and performs worse in key subgroups. If a stem offers dopamine as a nostalgic distractor, remember that large randomized data in shock populations found more arrhythmias with dopamine, and a signal toward harm in cardiogenic shock subgroup analyses. The exam often frames this as “more tachyarrhythmias” and “worse outcomes.”

Practical takeaway for boards: in septic shock, pick norepinephrine first unless a question explicitly removes it from options.

When to add vasopressin in sepsis (and what it’s really doing)

Vasopressin is not “second-line because it’s weak.” It’s second-line because it is best used as an adjunct: a non-catecholamine way to raise SVR and reduce the catecholamine dose you need (often called “norepinephrine-sparing”). In septic shock, endogenous vasopressin levels can become inappropriately low for the degree of vasodilation (“relative deficiency”), which is why low-dose replacement makes physiologic sense.

Board triggers to reach for vasopressin

Persistent hypotension despite escalating norepinephrine and adequate fluid resuscitation.
Need to limit catecholamines (tachyarrhythmia risk, severe tachycardia, high-dose norepi).
“Refractory vasoplegia” language: warm shock, wide pulse pressure, MAP not holding.

Dose: memorize one number, understand the intent

Most exam stems and many real protocols use a fixed low dose rather than titration: 0.03 units/min is the classic anchor. Think “hormone replacement dose,” not “turn it up until the toes fall off.”

Safety pearl: excessive vasoconstriction risks digital and splanchnic ischemia—boards love the “cold digits” complication.

What to do if norepi + vasopressin still isn’t enough

At that point, the question becomes: is this still pure vasodilation, or has cardiac output fallen (septic cardiomyopathy)? If the patient is warm but profoundly hypotensive, another pressor (often epinephrine in many algorithms) may be layered. If the patient is cold with poor perfusion, you should think “add inotropy” rather than endlessly squeezing the vasculature.

If still warm/vasoplegic:

Add another vasopressor class (commonly epi) while reassessing source control and fluid responsiveness.

If now cold/low-output:

Consider dobutamine when perfusion is low despite acceptable MAP and volume status.

Score stuck after more questions? Free reasoning diagnostic

Clinical stems are easier when you can see the decision being tested.

MDSteps helps you separate diagnosis, management, disposition, prevention, counseling, and timing so the next step stops feeling subjective.

Pivot clue isolatedDistractor trap explainedNext study target identified

Practice Clinical Decisions Practice clinical decisions

Not ready yet? See why score plateaus happen · Read student examples · View features

No credit card required for the free reasoning review. Full access is $27/month after that. Cancel anytime.

Reasoning diagnostic

Still missing questions you thought you understood?

Find the clue that should have changed your answer
See why the distractor felt right
Turn repeated misses into targeted practice

Start Diagnostic Practice clinical decisions

Still missing the same kinds of questions? Read why that happens.

Epinephrine: the “power tool” (useful, but messy)

Epinephrine is the drug that can look like the right answer for almost any shock stem because it has both β and α activity. That’s also why it becomes an NBME trap: epinephrine can raise MAP, but it can also create confusing metabolic and rhythm effects that make monitoring and interpretation harder. On boards, epinephrine is best understood as an agent you pick when you need more inotropy plus vasoconstriction, or when first-line agents are unavailable.

When epi shows up as the correct choice

Refractory septic shock after norepi ± vasopressin (especially if additional support is needed).
Anaphylaxis (this is a separate world: epi is first-line because it reverses bronchospasm and vasodilation).
Cardiac arrest algorithms (ACLS context; different reasoning than shock titration).

Classic “epi side-effects” the exam likes

Tachyarrhythmias (β1): palpitations, ventricular ectopy, AF with RVR.
Lactate rise: not always “worsening sepsis”; can be β2-driven metabolic effect.
Hyperglycemia and increased myocardial oxygen demand.

High-yield compare: epi alone vs norepi + dobutamine

A common vignette asks you to choose between “one strong drug” and “a targeted combination.” In septic shock with myocardial dysfunction, a strategy of norepinephrine for tone plus dobutamine for forward flow can be comparable to epinephrine alone in efficacy, but epinephrine tends to bring more tachycardia and higher lactate. On USMLE, if the stem emphasizes low cardiac output signs (cool extremities, low urine output, echo with poor EF) after MAP is already acceptable, the combination logic becomes more compelling than reflex epi.

Exam phrasing to watch: “lactate rising after epinephrine started” may be a pharmacologic effect, not necessarily treatment failure.

Cardiogenic shock: pressors support pressure, inotropes support flow

Cardiogenic shock is a pump failure problem: low CO leads to hypotension and hypoperfusion. The temptation is to “fix the number” (MAP) with pure vasoconstriction, but excessive afterload can further reduce stroke volume. The USMLE move is to balance: restore perfusion pressure enough to maintain coronary and cerebral flow while also improving forward flow. That’s why cardiogenic shock often involves both a vasopressor (for MAP) and an inotrope (for CO).

When norepinephrine is the “pressor” for cardiogenic shock

Hypotension with signs of hypoperfusion (cold, clammy, altered, oliguria) → you need MAP support.
Norepi raises SVR with less tachy than dopamine and can modestly support contractility via β1.
Especially relevant in AMI with shock, where arrhythmias are already a threat.

What not to do (common distractors)

Don’t start dobutamine if the patient is profoundly hypotensive and vasodilated—β2 can drop SVR further.
Don’t choose dopamine as a “renal perfusion” fix; the exam trend favors norepi due to arrhythmia risk.
Don’t ignore mechanical causes (tamponade, tension pneumothorax, massive PE) in “shock” stems.

Mini-flowchart: cardiogenic shock vasoactive sequence

Confirm cardiogenic physiology: pulmonary edema, S3, high JVP, echo with low EF, ischemic symptoms.
If MAP low: start norepinephrine to prevent coronary hypoperfusion.
If perfusion still poor: add dobutamine to raise CO (watch HR and BP).
If refractory: think mechanical circulatory support and definitive therapy (PCI for AMI, valve intervention, etc.).

NBME trap: “Give fluids” is not the automatic answer in cardiogenic shock—look for pulmonary edema and high JVP.

Dobutamine: the inotrope you choose when “flow” is the problem

Dobutamine is a β1-predominant inotrope that increases contractility and (often) heart rate. It can also reduce afterload via β2, which is helpful when the failing ventricle needs to eject against a high resistance—but risky if blood pressure is already marginal. The USMLE pattern: dobutamine is correct when the question emphasizes ongoing hypoperfusion despite adequate MAP and volume, or when cardiogenic shock needs a “push” to restore forward flow.

High-yield indications

Cardiogenic shock with low CO (cold extremities, low urine output) when MAP is supported (often by norepi).
Septic shock with myocardial dysfunction and persistent hypoperfusion after fluids and achieving MAP target.
Bridge while definitive therapy occurs (revascularization, diuresis/afterload reduction, mechanical support).

Side effects & pitfalls

Tachyarrhythmias and increased myocardial oxygen demand (watch in ischemia).
Hypotension from β2 vasodilation—especially if you start it without pressor support.
“Looks better, still shock”: CO improves but lactate/urine output may lag; reassess source/volume/bleeding.

Exam move: decide whether you need “more pressure” or “more flow”

Finding	Suggests	Typical move
Warm, vasodilated, MAP low	Low SVR	Norepi first; add vasopressin if escalating
Cold, clammy, pulmonary edema, MAP low	Low CO + low perfusion pressure	Norepi to support MAP; then add dobutamine if needed
MAP okay but lactate high, oliguria persists	Ongoing hypoperfusion (often low flow)	Consider dobutamine after ensuring volume and ruling out obstruction
Tachyarrhythmia after vasoactive start	Excess β stimulation	Reconsider epi/dobutamine dose; correct electrolytes/ischemia

MDSteps workflow tip (optional, but clutch)

If you’re drilling shock pharmacology, pair a short “hemodynamic bucket” note with each miss and let the platform generate flashcards from your wrong-answer logic. In MDSteps, the Adaptive QBank and missed-question flashcard deck can turn this topic into a spaced pattern—rather than a one-time memorization pass.

Mixed shock and the “two-number” trap: MAP vs perfusion

Real patients (and good exam writers) love mixed shock: sepsis with new heart failure, massive MI with inflammatory vasodilation, pancreatitis with hypovolemia plus distributive features. Mixed shock is where students either overtreat SVR (making the heart fail harder) or overtreat CO (making blood pressure collapse). The solution is to manage two goals simultaneously: perfusion pressure (MAP) and forward flow (CO), guided by end-organ perfusion.

Signs you’re dealing with mixed physiology

Infection clues plus cool extremities or new pulmonary edema.
Echo: reduced EF in a patient who “should” be warm septic.
MAP improves with norepi, but lactate/urine output remain poor.
Pressor doses climb quickly with minimal MAP response (vasoplegia) and perfusion remains bad.

A practical mixed-shock strategy (USMLE-ready)

Use norepi to secure a perfusion floor (MAP goal).
Add vasopressin if escalating catecholamines are needed.
If perfusion still poor and the patient is not fluid responsive, add dobutamine (or consider epi depending on the stem).
Keep searching for the reversible driver: source control, revascularization, bleeding, tamponade/PE.

Common NBME-style pitfalls (memorize these as “wrong-answer magnets”)

Pitfall: “BP is 92/58 so give dobutamine.”

If the patient is vasodilated, dobutamine can worsen hypotension. Start with norepi to stabilize MAP first.

Pitfall: “Lactate rose after starting epi = sepsis worsening.”

Epi can raise lactate via β2 effects. Look at perfusion, urine output, and trend after resuscitation.

Pitfall: “Add vasopressin and titrate high until MAP is normal.”

Low-dose adjunct is the board-relevant concept; high doses increase ischemic risk.

Pitfall: “Pressors fix shock even without source control.”

For sepsis, antibiotics and source control are definitive; pressors buy time.

Rapid-Review Checklist: choosing the right agent in 15 seconds

This is your last-minute, exam-day pattern recognition list. Read the stem, identify the shock bucket, and select the vasoactive that fixes the dominant problem while avoiding the predictable complication.

Checklist

Septic shock (warm, vasodilated): start norepinephrine after fluids; target MAP ≈ 65.
Escalating norepi need: add vasopressin (low-dose adjunct; think catecholamine-sparing).
Still hypotensive or need more “push”: consider epinephrine (watch tachy, lactate interpretation).
Cardiogenic shock with hypotension: use norepinephrine to support MAP; then add dobutamine if low-output persists.
Cardiogenic shock without severe hypotension: an inotrope strategy can be emphasized; avoid dropping SVR too far.
Mixed shock: secure MAP first (norepi), then optimize flow (dobutamine) if perfusion remains poor.
Always reassess perfusion: mentation, urine output, lactate trend, cap refill—not just the BP number.

One-table summary (printable)

Scenario	Best first move	Then…
Septic shock, MAP low	Norepi	Add vasopressin if escalating
Septic shock, refractory	Norepi + vasopressin	Consider epi; recheck perfusion + source control
Cardiogenic shock, hypotensive	Norepi	Add dobutamine for low CO
Low CO, MAP acceptable	Dobutamine	Watch tachy/hypotension; treat cause

If you want to make this automatic, set up a “shock” tag set in your QBank reviews and track which bucket you missed most. The MDSteps analytics dashboard can make that visible fast.

Exam-Day Essentials

Sepsis management is not “pressors only”: early antibiotics and source control are the definitive steps.
In cardiogenic shock, think: perfusion pressure + forward flow; avoid pure afterload increase without CO support.
Epi can raise lactate; interpret trends in context of perfusion and the timeline of drug initiation.
When options include dopamine, remember arrhythmias and poorer outcomes in cardiogenic shock subgroup analyses.

References (external)

Medically reviewed by

Ryan K. Lee, MD (Emergency Medicine)